NNC0385-0434 G
DrugParticipants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
NCT Number: NCT05333107
In this study, the study drug 'NNC0385-0434' will be tested in 3 different tablet formulations. These formulations are being tested for the treatment of hypercholesterolemia (high cholesterol). Participants will only receive 2 of the 3 tablet formulations. The treatments participants get are decided by chance. Participants will receive 1 formulation for 10 days (first treatment period) and the other formulation for 5 days (second treatment period). The study will last up to 96 days. Only men can participate in this clinical study.
Looking for future studies?
Notify Me18 year–64 year
Male
Interventional
Phase 1
Altasciences, Cypress, California, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Time frame: From 0 to 24 hours after dose administration on visit 2, day 10
Measured in h * nmol/L
Time frame: From 0 to 24 hours after dose administration on visit 2, day 10
Measured in nmol/L
Time frame: From 0 to 24 hours after dose administration on visit 2, day 10
Measured in hours
Novo Nordisk A/S
Industry
A Study Investigating the Pharmacokinetic Properties When Dosing Different Formulations of NNC0385-0434 to Healthy Male Participants - Oral Formulation II
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07740473
Body Weight, Body Weight Changes
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT00001204
Arterial Occlusive Diseases, Arteriosclerosis
Bethesda, Maryland, United States
View Trial DetailsNCT06837077
Dyslipidemias, Hypercholesterolemia
Hefei, Anhui, China
View Trial DetailsNCT07737067
Arthrosclerosis, Dyslipidemias
Lahore, Punjab Province, Pakistan
View Trial Details